Teng Zenghui
Medical Faculty, Institute of Neuro- and Sensory Physiology, Heinrich-Heine-University Düsseldorf, Germany.
J Alzheimers Dis Rep. 2024 Feb 20;8(1):345-354. doi: 10.3233/ADR-230130. eCollection 2024.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease with cognitive decline and behavioral dysfunction. AD will become a global public health concern due to its increasing prevalence brought on by the severity of global aging. It is critical to understand the pathogenic mechanisms of AD and investigate or pursue a viable therapy strategy in clinic. Amyloid-β (Aβ) accumulation and abnormally hyperphosphorylated tau protein are the main regulating variables in the pathological phase of AD. And neuroinflammation brought on by activated microglia was found to be one risk factor contributing to changes in Aβ and tau pathology. It is important to investigate the unique biomarkers of early diagnosis and advanced stage, which may help to elucidate the specific pathological process of AD and provide potential novel therapeutic targets or preventative measures.
阿尔茨海默病(AD)是最常见的神经退行性疾病,伴有认知衰退和行为功能障碍。由于全球老龄化的加剧导致其患病率不断上升,AD将成为一个全球公共卫生问题。了解AD的致病机制并在临床上研究或寻求可行的治疗策略至关重要。淀粉样β蛋白(Aβ)积累和异常过度磷酸化的tau蛋白是AD病理阶段的主要调节变量。并且发现由活化的小胶质细胞引起的神经炎症是导致Aβ和tau病理变化的一个危险因素。研究早期诊断和晚期的独特生物标志物很重要,这可能有助于阐明AD的具体病理过程,并提供潜在的新型治疗靶点或预防措施。